Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.65
+2.7%
$1.59
$1.23
$5.50
$62.43M-0.38840,010 shs262,662 shs
Moderna, Inc. stock logo
MRNA
Moderna
$30.47
+0.6%
$26.72
$23.15
$129.39
$11.79B1.848.69 million shs6.97 million shs
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$5.01
+5.9%
$4.18
$2.76
$6.00
$229.54M0.4115,394 shs809 shs
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$2.14
+0.6%
$1.81
$1.07
$4.62
$229.36M0.36657,433 shs175,653 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metagenomi, Inc. stock logo
MGX
Metagenomi
0.00%+13.29%-2.71%+17.30%-57.70%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+12.19%+11.73%+21.35%-73.72%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
0.00%+8.68%+10.11%+53.21%-7.14%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
0.00%+5.05%+18.40%+81.61%+30.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Metagenomi, Inc. stock logo
MGX
Metagenomi
1.7953 of 5 stars
3.52.00.00.00.01.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.3888 of 5 stars
4.02.00.04.61.32.50.6
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
1.7075 of 5 stars
3.33.00.00.01.10.00.6
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
2.1632 of 5 stars
3.63.00.00.03.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Metagenomi, Inc. stock logo
MGX
Metagenomi
3.00
Buy$13.00685.97% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6152.97% Upside
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$8.0059.68% Upside
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
3.13
Buy$8.00273.31% Upside

Current Analyst Ratings Breakdown

Latest MGX, MRNA, PRQR, and NBTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$8.00
6/27/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$8.00
6/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$33.00 ➝ $26.00
5/15/2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $12.00
5/14/2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$20.00 ➝ $16.00
5/13/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $70.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$45.00 ➝ $40.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$32.00 ➝ $28.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$50.00 ➝ $32.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Metagenomi, Inc. stock logo
MGX
Metagenomi
$52.29M1.18N/AN/A$6.28 per share0.26
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.64N/AN/A$28.33 per share1.08
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$39.18M6.03N/AN/A($1.51) per share-3.32
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$20.46M11.02N/AN/A$0.91 per share2.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$78.06M-$2.11N/AN/AN/A-172.21%-31.21%-22.21%8/13/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%7/30/2025 (Estimated)
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$73.73MN/A0.00N/AN/AN/AN/AN/A9/16/2025 (Estimated)
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$30.04M-$0.35N/AN/AN/A-157.04%-53.49%-22.07%8/4/2025 (Estimated)

Latest MGX, MRNA, PRQR, and NBTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.62-$0.68-$0.06-$0.68$8.75 million$4.13 million
5/8/2025Q1 2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 million
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
5.85
5.85
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/A
1.04
1.04
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
38.81%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
32.65%

Insider Ownership

CompanyInsider Ownership
Metagenomi, Inc. stock logo
MGX
Metagenomi
17.80%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
3.45%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Metagenomi, Inc. stock logo
MGX
Metagenomi
23637.38 million30.73 millionN/A
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
10047.13 million45.51 millionNot Optionable
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
180105.21 million96.38 millionOptionable

Recent News About These Companies

PRQR - ProQR Therapeutics NV Sustainability - Morningstar
PRQR - ProQR Therapeutics NV Key Metrics - Morningstar
ProQR Therapeutics N.V. (PRQR) - Yahoo Finance
Cantor Fitzgerald Comments on PRQR FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Metagenomi stock logo

Metagenomi NASDAQ:MGX

$1.65 +0.04 (+2.73%)
Closing price 07/3/2025 03:43 PM Eastern
Extended Trading
$1.66 +0.00 (+0.06%)
As of 07/3/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$30.47 +0.19 (+0.63%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$30.50 +0.03 (+0.08%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$5.01 +0.28 (+5.92%)
Closing price 07/3/2025 03:29 PM Eastern
Extended Trading
$5.08 +0.08 (+1.50%)
As of 07/3/2025 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

ProQR Therapeutics stock logo

ProQR Therapeutics NASDAQ:PRQR

$2.14 +0.01 (+0.52%)
As of 07/3/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.